登革热疫苗:WHO立场文件(2018年9月)——建议摘要
本文摘录WHO 2018年9月登革热疫苗立场文件中的建议,取代2016年7月关于首个获批登革热疫苗CYD-TDV的立场文件。文件从人群健康角度提供登革热疫苗接种策略的修订指导。
要点
- 血清阴性者接种CYD-TDV后严重登革热风险高于血清阴性未接种者。
- 血清阳性者接种CYD-TDV可获得长期保护。
- WHO根据上述证据修订登革热疫苗接种策略,指导大规模免疫规划。
核心结论
- 血清阴性个体接种CYD-TDV存在严重登革热超额风险,而血清阳性个体可获得长期保护。
- WHO据此从人群健康角度修订登革热疫苗接种策略建议。
研究设计与样本
- 新证据来自一项临床试验数据的回顾性分析,采用新血清学检测按首次接种前登革热血清状态对试验参与者分类。
主要发现
- 血清阴性疫苗接种者较血清阴性未接种者存在严重登革热超额风险。
- 血清阳性个体接种后确认获得长期保护。
临床怎么用
- 在制定登革热疫苗接种策略时,应依据接种前登革热血清状态评估风险与获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This article presents the World Health Organization's (WHO) recommendations on the use of dengue vaccine excerpted from the WHO position paper on dengue vaccine - September 2018, published in the Weekly Epidemiological Record [1]. This position paper replaces the July 2016 WHO position paper concerning the first licensed dengue vaccine, CYD-TDV [2]. The position paper presents new evidence that became available in November 2017. A retrospective analysis of data from clinical trials, using a new serological assay classified trial participants according to their dengue serostatus prior to receipt of the first vaccine dose. The analysis revealed an excess risk of severe dengue in seronegative vaccine recipients compared to seronegative non-vaccinated individuals, while confirming long-term protection in seropositive individuals [3]. The paper provides revised guidance on dengue vaccination strategies from a population health perspective. Footnotes to this paper provide a number of core references including references to grading tables that assess the quality of the scientific evidence, and to the evidence-to-recommendation table. In accordance with its mandate to provide guidance to Member States on health policy matters, WHO issues a series of regularly updated position papers on vaccines and combinations of vaccines against diseases that have an international public health impact. These papers are concerned primarily with the use of vaccines in large-scale immunization programmes; they summarize essential background information on diseases and vaccines, and conclude with WHO's current position on the use of vaccines in the global context. Recommendations on the use of dengue vaccine CYD-TDV were discussed by SAGE in April 2018; evidence presented at the meeting can be accessed at: http://www.who.int/immunization/sage/meetings/2018/april/presentations_background_docs/en/.
引用
- Dengue vaccine: WHO position paper, September 2018 - Recommendations. Vaccine. 2018. PMID: 30424888. doi:10.1016/j.vaccine.2018.09.063
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。